Medtronic issued a voluntary global recall of its Octopus 4 Tissue Stabilizer after identifying an assembly issue during ...

Medtronic MDT posted solid fiscal first-quarter results that held few surprises and put the firm on track to meet our full-year expectations. We’re leaving our $112 fair value estimate unchanged, and ...

Medtronic gains attention as renal denervation optimism, revenue growth, cardiac care, and diabetes technology reshape its ...

For years, investors questioned whether Medtronic was moving quickly and innovating enough. Now, the company is answering with its checkbook. So far in 2026, the Minnesota-run medical device maker has ...

Medtronic ended its fiscal year with nominal sales growth and a steep profit drop, but analysts who cover the medical device company are confident a windfall is ahead, thanks to a strong lineup of ...

Medtronic (NYSE:MDT) has notified individuals affected by a cyberattack, outlining data security steps and offering identity ...

Medtronic’s board of directors gave Geoff Martha the luxury and burden of eight months of time to think about how he would succeed Omar Ishrak as CEO of the medical technology giant. When Medtronic ...

Medtronic (NYSE: MDT) posted first-quarter earnings (for the period ended on June 30) that exceeded the average of Wall Street estimates. The results were strong enough for the medical technologies ...

Two patients who were injured by Medtronic's controversial Infuse bone graft product will receive a combined $8.45 million in settlements with the University of California Los Angeles, where a doctor ...

Medtronic is renowned for revolutionizing healthcare through groundbreaking innovations, from pioneering the first implantable cardiac pacemakers to developing state-of-the-art minimally invasive ...

Narrow-moat Medtronic wrapped up its fiscal year with solid fourth-quarter results. With full fiscal year performance hitting very close to our estimates and our projections for fiscal 2025 bounded by ...